4 Einträge von 5 mit patients immunoglobulins
www.cslbehring.ch
Datum der Indexierung 13.03.2021 22:53:57
erkannte Namen Alex Gertsch | Gérard Jenni | Georg Ptak | Patricia Stutz | Philip Kissling | Valentin Kressler | Rolf Vennenbernd |
weitere Namen in www.cslbehring.ch 7
Subdomain:
extern (outbound) Link/Domain 0 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description pdf
Kombination Keywords phase patients | global vaccine | specialty cidp | haemophilia development | medicines study | breakthrough efficacy | products clinical | immunoglobulins privigen | with afstyla | afluria market |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
patients will progress to wheelchair dependence • IVIG as first line therapy Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Immunoglobulins 34 PATH Program – Phase III Study 1 • Largest placebo controlled study in CIDP • Data base locked • Immunoglobulins & Specialty Products • Clinical Development Charmaine Gittleson • Commercial Opportunities Bob Repella • Q&A - Break - • Coagulation/Haemophilia • Clinical Development Charmaine Gittleson • Commercial Opportunities
Text Inhalt Text aus URL
Log Metriken 446030
erkannte Namen Alex Gertsch | Gérard Jenni | Georg Ptak | Patricia Stutz | Philip Kissling | Valentin Kressler | Rolf Vennenbernd |
weitere Namen in www.cslbehring.ch 7
Subdomain:
extern (outbound) Link/Domain 0 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description pdf
Kombination Keywords phase patients | global vaccine | specialty cidp | haemophilia development | medicines study | breakthrough efficacy | products clinical | immunoglobulins privigen | with afstyla | afluria market |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
patients will progress to wheelchair dependence • IVIG as first line therapy Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Immunoglobulins 34 PATH Program – Phase III Study 1 • Largest placebo controlled study in CIDP • Data base locked • Immunoglobulins & Specialty Products • Clinical Development Charmaine Gittleson • Commercial Opportunities Bob Repella • Q&A - Break - • Coagulation/Haemophilia • Clinical Development Charmaine Gittleson • Commercial Opportunities
Text Inhalt Text aus URL
Log Metriken 446030
www.cslbehring.ch
Datum der Indexierung 25.04.2021 00:31:15
erkannte Namen Alex Gertsch | Gérard Jenni | Georg Ptak | Patricia Stutz | Philip Kissling | Valentin Kressler | Rolf Vennenbernd |
weitere Namen in www.cslbehring.ch 7
Subdomain:
extern (outbound) Link/Domain 0 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description pdf
Kombination Keywords phase japan | global efficacy | specialty clinical | breakthrough research | haemophilia briefing | medicines investor | products privigen | immunoglobulins afstyla | with market | afluria development |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
patients will progress to wheelchair dependence • IVIG as first line therapy Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Immunoglobulins 34 PATH Program – Phase III Study1 • Largest placebo controlled study in CIDP • Data base locked • H Immunoglobulins & Specialty Products • Clinical Development Charmaine Gittleson • Commercial Opportunities Bob Repella • Q&A - Break - • Coagulation/Haemophilia • Clinical Development Charmaine Gittleson • Commercial Opportunities
Text Inhalt Text aus URL
Log Metriken 563122
erkannte Namen Alex Gertsch | Gérard Jenni | Georg Ptak | Patricia Stutz | Philip Kissling | Valentin Kressler | Rolf Vennenbernd |
weitere Namen in www.cslbehring.ch 7
Subdomain:
extern (outbound) Link/Domain 0 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description pdf
Kombination Keywords phase japan | global efficacy | specialty clinical | breakthrough research | haemophilia briefing | medicines investor | products privigen | immunoglobulins afstyla | with market | afluria development |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
patients will progress to wheelchair dependence • IVIG as first line therapy Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Immunoglobulins 34 PATH Program – Phase III Study1 • Largest placebo controlled study in CIDP • Data base locked • H Immunoglobulins & Specialty Products • Clinical Development Charmaine Gittleson • Commercial Opportunities Bob Repella • Q&A - Break - • Coagulation/Haemophilia • Clinical Development Charmaine Gittleson • Commercial Opportunities
Text Inhalt Text aus URL
Log Metriken 563122
www.cslbehring.ch
Datum der Indexierung 05.05.2021 18:09:26
erkannte Namen Gérard Jenni | Alex Gertsch | Georg Ptak | Bill Mezzanotte | Jérôme Gremaud | Burkhard Statutory | Corona Anderer |
weitere Namen in www.cslbehring.ch 7
Subdomain:
extern (outbound) Link/Domain 0 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description pdf?la=de-de&hash=B3ECD0C4EC5CADE10D984FB30A7059E7D56691C0
Kombination Keywords phase privigen | with market | transplant clinical | anti study | cidp research | products hizentra | breakthrough global | medicines development | patients immunoglobulins | haemophilia specialty |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
patients: 155,000 (US + 5EU) 19 • CAL-H program aims to provide sufficient functional globin gene to prevent sickling shRNA β pro 7SK γ-globin exons LCR HPRT shRNA Cytegrity™ lenti-backbone Select+™ technology SIN-LV γ-globin construct (sGbG M) https Immunoglobulins, Haemophilia and Specialty Products – Clinical Development Bill Mezzanotte – Commercial Opportunities Bill Campbell • Q&A – Break – • Transplant and Breakthrough Medicines (CSL112) – Clinical Development Bill Mezza
Text Inhalt Text aus URL
Log Metriken 446028
erkannte Namen Gérard Jenni | Alex Gertsch | Georg Ptak | Bill Mezzanotte | Jérôme Gremaud | Burkhard Statutory | Corona Anderer |
weitere Namen in www.cslbehring.ch 7
Subdomain:
extern (outbound) Link/Domain 0 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description pdf?la=de-de&hash=B3ECD0C4EC5CADE10D984FB30A7059E7D56691C0
Kombination Keywords phase privigen | with market | transplant clinical | anti study | cidp research | products hizentra | breakthrough global | medicines development | patients immunoglobulins | haemophilia specialty |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
patients: 155,000 (US + 5EU) 19 • CAL-H program aims to provide sufficient functional globin gene to prevent sickling shRNA β pro 7SK γ-globin exons LCR HPRT shRNA Cytegrity™ lenti-backbone Select+™ technology SIN-LV γ-globin construct (sGbG M) https Immunoglobulins, Haemophilia and Specialty Products – Clinical Development Bill Mezzanotte – Commercial Opportunities Bill Campbell • Q&A – Break – • Transplant and Breakthrough Medicines (CSL112) – Clinical Development Bill Mezza
Text Inhalt Text aus URL
Log Metriken 446028
www.cslbehring.ch
Datum der Indexierung 05.05.2021 07:42:21
erkannte Namen Gérard Jenni | Alex Gertsch | Georg Ptak | Bill Mezzanotte | Jérôme Gremaud | Burkhard Statutory | Corona Anderer |
weitere Namen in www.cslbehring.ch 7
Subdomain:
extern (outbound) Link/Domain 0 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description pdf
Kombination Keywords phase privigen | with market | transplant clinical | anti study | cidp research | products hizentra | breakthrough global | medicines development | patients immunoglobulins | haemophilia specialty |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
patients: 155,000 (US + 5EU) 19 • CAL-H program aims to provide sufficient functional globin gene to prevent sickling shRNA β pro 7SK γ-globin exons LCR HPRT shRNA Cytegrity™ lenti-backbone Select+™ technology SIN-LV γ-globin construct (sGbG M) https Immunoglobulins, Haemophilia and Specialty Products – Clinical Development Bill Mezzanotte – Commercial Opportunities Bill Campbell • Q&A – Break – • Transplant and Breakthrough Medicines (CSL112) – Clinical Development Bill Mezza
Text Inhalt Text aus URL
Log Metriken 469967
erkannte Namen Gérard Jenni | Alex Gertsch | Georg Ptak | Bill Mezzanotte | Jérôme Gremaud | Burkhard Statutory | Corona Anderer |
weitere Namen in www.cslbehring.ch 7
Subdomain:
extern (outbound) Link/Domain 0 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description pdf
Kombination Keywords phase privigen | with market | transplant clinical | anti study | cidp research | products hizentra | breakthrough global | medicines development | patients immunoglobulins | haemophilia specialty |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
patients: 155,000 (US + 5EU) 19 • CAL-H program aims to provide sufficient functional globin gene to prevent sickling shRNA β pro 7SK γ-globin exons LCR HPRT shRNA Cytegrity™ lenti-backbone Select+™ technology SIN-LV γ-globin construct (sGbG M) https Immunoglobulins, Haemophilia and Specialty Products – Clinical Development Bill Mezzanotte – Commercial Opportunities Bill Campbell • Q&A – Break – • Transplant and Breakthrough Medicines (CSL112) – Clinical Development Bill Mezza
Text Inhalt Text aus URL
Log Metriken 469967